ST-539


CAS No. : 1040754-67-3

1040754-67-3
Price and Availability of CAS No. : 1040754-67-3
Size Price Stock
5mg $612 In-stock
10mg $918 In-stock
25mg $1653 In-stock
50mg $2645 In-stock
100mg $4230 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-114383
M.Wt: 529.65
Formula: C30H31N3O4S
Purity: >98 %
Solubility: DMSO : 100 mg/mL (ultrasonic)
Introduction of 1040754-67-3 :

ST-539 is an orally active USP30 inhibitor that crosses the blood-brain barrier, with an IC50 of 0.37 μM. ST-539 blocks USP30-mediated removal of ubiquitin from Parkin substrates, induces Parkin-mediated mitophagy and apoptosis during mitochondrial stress, and inhibits the AKT/mTOR signaling pathway. ST-539 can be used for research on T-cell leukemia, Parkinson's disease, and colon adenocarcinoma[1][2][3][4]. In Vitro:ST-539 improves the mitochondrial fitness of Pmel-1 antigen-specific CD8+ T cells, reduces the expression of exhaustion markers, and enhances effector function[3].
ST-539 (10 μM; added on day 4 of an 8-day culture and maintained through the remaining culture period) enhances mitochondrial efficiency and granzyme B in chronically stimulated human CBMC-derived CD8+ T cells while decreasing Lag3[3].
ST-539 restores mitophagy and mitochondrial fitness in chronically stimulated mouse CD8+ T cells while reducing exhaustion and increasing granzyme B[3].
ST-539 (41 ng/mL-10 µg/mL; 72 h) enhances MK-2206 (HY-108232)-mediated growth inhibition of Jurkat T leukemia cells[1].
ST-539 (48 h) produces synergistic effects with PI3K/Akt/mTOR inhibitors in Jurkat T leukemia cells, where Indirubin (HY-N0117) combined with ST-539 reduces cell growth by 48%[1].
ST-539 (10 μg/mL) has minimal direct cytotoxicity against MC38 tumor cells and a slight effect on T cell expansion[3].
ST-539 (24 h) enhances MK-2206-induced AKT inhibition and apoptosis in Jurkat T leukemia cells[1].
ST-539 (10 µg/mL; 48 h) enhances AKT/mTOR inhibitor-induced loss of cell viability in Hela Parkin USP30 cells[1].
ST-539 (10 µg/mL; 0-6 h) inhibits USP30 in Hela Parkin USP30 cells, reduces AKT levels, and promotes Parkin-mediated mitophagy and apoptosis during AO-induced mitochondrial stress[1].
ST-539 (3 μg/mL) restores A/O-induced mitophagy in USP30-overexpressing HeLa-Parkin cells[4].
ST-539 (1-3 μg/mL; 18 h) requires functional PINK1/Parkin to promote TOM20 ubiquitination and reduce TOM20 and NDP52 in HeLa-Parkin cells[4].
ST-539 (1-10 μg/mL) promotes USP30-inhibitable mitophagy in HeLa-Parkin cells and restores A/O-induced ubiquitination of TOM20 and degradation of TIM23 and TOM40[4].
ST-539 (compound 14) inhibits USP30 with an IC50 of 0.37 μM[2]. In Vivo:ST-539 (0.5 mg per mouse; oral gavage; once every other day) reduces MC38 tumor growth and enhances the mitochondrial fitness and granzyme B expression of tumor-infiltrating CD8+ T cells[3].
ST-539 (25 mg/kg/day; intraperitoneal injection; once daily; 5 doses in total) inhibits USP30 and selectively increases cardiac mitophagy in vivo without impairing cardiac function[4].

Your information is safe with us.